[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ventricular-arrythmia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ventricular-arrythmia":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,23,0,[8,45,59,84,105,141,164,190,216,259,287,311,338,363,393,422,460,487,509,532,586,614,644],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100054135","parasternal-extravascular-icd-system-pivotal-clinical-investigation-alarion-ev-study-100054135",false,"NCT07324031","Parasternal Extravascular ICD System Pivotal Clinical Investigation (ALARION EV) Study","ALARION EV","Inclusion Criteria:\n\n1. At least 18 years old\n2. Class I or IIa indication for implantation of an ICD according to the ACC\u002FAHA\u002FHRS Guidelines or ESC guidelines\n\nExclusion Criteria:\n\n1. Patients who cannot read or write\n2. Expected survival \\\u003C 1 year\n3. Pregnant or nursing subjects and those who plan pregnancy during the clinical investigation follow-up period\n4. Participation in any concurrent clinical study without prior approval from the Sponsor\n5. Inability or unwillingness to provide informed consent to participate in the study\n6. Any known circumstances which may prevent the completion of protocol testing and data collection through the 6-month follow-up visit\n7. Circumstances that may prevent data collection or completion of specified follow-up visits\n8. Allergies to any device materials listed in the Instructions for Use (IFU)\n9. Contraindication for temporary suspension of oral\u002Fsystemic anticoagulation\n10. Known history of lung disease with FEV1 \\\u003C 1.0 Liter\n\n    Device Related:\n11. Implanted with or planned implantation of any device which delivers current in the body that may interfere with therapy delivery, including, but not limited to a pacemaker, LVAD or neurostimulator\n12. Implanted with a subcutaneous ICD lead, subcutaneous coils\u002Farrays, epicardial patches or epicardial pace\u002Fsense leads\n13. Any known need for MRI prior to approval of MRI conditional labeling\n\n    Anatomy Related:\n14. Known structural abnormalities of the heart that may increase risk of the Parasternal EV-ICD System procedure\n15. Known obstructed or restricted pathway into the mediastinum for the Atala™ lead\n16. Prior surgery with disruption of the lung, pericardium or connective tissue between the sternum and pericardium, including sternotomy of any type\n17. Known significant anatomic derangement of or within the thorax (e.g., pectus excavatum, significant scoliosis)\n18. History of thoracic radiation therapy or other medical treatments\u002Fconditions which may complicate the Parasternal EV-ICD System implant procedure\n19. Known adhesions in the thorax or history of medical treatments, surgeries or conditions that increase the potential for adhesions in the thorax\n20. Surgically corrected congenital heart disease (not including catheter-based procedures)\n\n    Cardiac Related:\n21. Indication for permanent bradycardia pacing or cardiac resynchronization therapy\n22. Decompensated heart failure\n23. Currently on inotropic therapy\n24. Known history of pericardial disease, pericarditis or mediastinitis\n25. Risk factors associated with defibrillation testing:\n\n    * Severe aortic stenosis\n    * Current Intracardiac LA or LV thrombus\n    * Severe proximal three-vessel or left main coronary artery disease without revascularization\n    * Hemodynamic instability\n    * Unstable angina\n    * Recent stroke or transient ischemic attack (within the last 3 months)\n    * Known inadequate external defibrillation\n    * LVEF \\\u003C 20% (most recent assessment; must be within 180 days of consent)\n    * LVEDD \\>70 mm (most recent assessment; must be within 180 days of consent)","ALL","18 Years",{"count":19,"type":20},280,"ESTIMATED","INTERVENTIONAL",[23],"NA","The ALARION EV Study is a prospective, multi-center, single-arm, non-randomized study without concurrent or historical controls. The purpose of this pivotal study is to generate evidence of safety and effectiveness to apply for regulatory approvals for commercialization of the Parasternal EV-ICD System.\n\nThe objective of the study is to demonstrate safety and effectiveness of the Parasternal EV-ICD System through 6-months.",[26,27,28],"Ventricular Arrythmia","Ventricular Fibrillation","Ventricular Tachycardia",[30,31],"Ventricular Defibrillation","Extravascular","RECRUITING","2026-07-10",{"date":35,"type":36},"2026-07-13","ACTUAL",{"date":38,"type":36},"2026-07-02",{"date":40,"type":20},"2028-12-31",{"name":42,"class":43},"AtaCor Medical, Inc.","INDUSTRY",35,{"id":46,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":21,"phases":48,"briefSummary":24,"conditions":49,"keywords":50,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":58,"locationsCount":4},"100617854",{"count":19,"type":20},[23],[26,27,28],[30,31],"NOT_YET_RECRUITING","2026-06-26",{"date":54,"type":36},"2026-06-30",{"date":56,"type":20},"2026-07-01",{"date":40,"type":20},{"name":42,"class":43},{"id":60,"slug":61,"hasResults":11,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":65,"eligibilityCriteria":66,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":67,"targetDuration":4,"studyType":21,"phases":69,"briefSummary":70,"conditions":71,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":83},"100545215","arrhythmic-mitral-valve-prolapse-detection-using-long-term-ambulatory-rhythm-monitoring-100545215","NCT06378996","Arrhythmic Mitral Valve Prolapse Detection Using Long-term Ambulatory Rhythm Monitoring","Arrhythmic Mitral Valve Prolapse Detection Using Long-term Ambulatory Rhythm - A Pilot Study","ALARM-PILOT","Inclusion Criteria:\n\n* Patients aged 18 years or older\n* Mitral valve prolapse diagnosed on previous echocardiography or cardiac MRI\n* New York Heart association classification ≥3 for cohort 3 and classification 1 or 2 for cohorts 1 and 2\n* Willing and able to provide signed written informed consent\n* No contra-indication for long-term monitoring (known allergy to adhesives)\n\nExclusion Criteria:\n\n* Prior cardiac surgery, including previous mitral valve intervention\n* Prior endovascular mitral valve repair (MitraClip)\n* Previous catheter ablation of ventricular arrhythmias\n* Patients not in sinus rhythm\n* Patients on anti-arrhythmic drugs but betablockers\n* Known alternative arrhythmic substrate, for example previous myocardial infarction\n* Known allergy to adhesives",{"count":68,"type":20},60,[23],"Mitral valve prolapse (MVP) affects up to 3% of the general population and a small subset of patients is at risk for ventricular arrhythmias. This subgroup is referred to as AMVP (arrhythmic MVP) and was recently defined using the following criteria: (1) Presence of MVP), (2) Ventricular arrhythmia that is either frequent (≥5% total premature ventricular contraction (PVC) burden on Holter) or complex (non-sustained ventricular tachycardia (nsVT), ventricular tachycardia (VT), or ventricular fibrillation (VF)), and (3) The absence of any other well-defined arrhythmic substrate.\n\nCurrently, diagnosis is often based on repeated 24-hour Holter monitoring. However, the ventricular arrhythmia burden varies from day-to-day and long-term rhythm monitoring has shown in other pathologies to increase the diagnostic yield with up to 200% (from 22.5% on 24h to 75.3% on 14 days).\n\nThis pilot study aims to study the diagnostic yield of long-term rhythm monitoring in patients with MVP as well as the day-to-day variability of ventricular arrhythmias to facilitate power calculation for a future large-scale prospective registry.",[72,26],"Mitral Valve Prolapse","2026-04-28",{"date":75,"type":36},"2026-05-05",{"date":77,"type":36},"2024-05-01",{"date":79,"type":20},"2026-06",{"name":81,"class":82},"Universitaire Ziekenhuizen KU Leuven","OTHER",1,{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":90,"enrollmentInfo":91,"targetDuration":4,"studyType":93,"phases":4,"briefSummary":94,"conditions":95,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":83},"100634546","the-comparative-advantage-of-the-optrell-mapping-catheter-in-ventricular-arrhythmias-from-the-papillary-muscles-100634546","NCT07541092","The Comparative Advantage of the Optrell Mapping Catheter in Ventricular Arrhythmias From the Papillary Muscles","Inclusion Criteria:\n\n* Patient or legally authorized representative (LAR) provides authorization and\u002For consent per institution and geographical requirements\n* Patient is not cognitively impaired, pregnant, prisoner, employed by Northwell, uninsured, or a student\n* Age 18-75 years old with the ability to consent for the procedure\n* Patient is consented within the enrollment window of the therapy received, as applicable\n* Patients with frequent (\\>10%) or symptomatic PVCs with ECG morphology consistent with papillary muscle origin.\n* Papillary muscle PVCs in setting of cardiomyopathy.\n* Patients prescribed by their treating physician to undergo the procedure with the Optrell™ mapping catheter as part of routine clinical care.\n* Patient demonstrates proficiency in the English language; reading, writing, and conversational\n\nExclusion Criteria:\n\n* Patient who is, or is expected to be, inaccessible for follow-up\n* Participation is excluded by local law\n* Patient is currently enrolled or plans to enroll in concurrent drug\u002Fdevice study that may confound the study results\n* Unable to consent\n* PVC from site other than papillary muscle\n* Acute coronary syndrome\n* Congestive heart failure in acute decompensation\n* Rapid atrial fibrillation\n* Requiring ventricular pacing","75 Years",{"count":92,"type":20},20,"OBSERVATIONAL","We believe that the design of the Optrell™ mapping catheter with TRUEref technology allows for faster and more accurate mapping not only due to narrow electrode spacing but also due to the ability to achieve simultaneous contact of multiple bipoles with the surface of the papillary muscle. Simultaneous mapping of multiple sites on the same surface will allow operators to appreciate small activation differences that typically exist between neighboring sites during papillary muscle ventricular arrhythmias. In addition, the position of the Optrell™ mapping catheter on the papillary muscle allows the mapping catheter to move with the papillary muscle rendering a more accurate allocation of the activation time to the surface of the papillary muscle. We also believe that optimal positioning between the Optrell™ mapping catheter and papillary muscles can be assisted by using intracardiac echocardiography. The goal of the study is to explore the utility and superiority of a specific mapping catheter, the Optrell™ mapping catheter with TRUEref.",[26],"2026-04-17",{"date":98,"type":36},"2026-04-21",{"date":100,"type":36},"2024-12-30",{"date":102,"type":20},"2028-12-30",{"name":104,"class":82},"Northwell Health",{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":21,"phases":115,"briefSummary":117,"conditions":118,"keywords":123,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":140},"100528279","phase-3-cmp-mythic-trial-and-registry---cardiomyopathy-with-myocarditis-therapy-with-colchicine-100528279","NCT06158698","CMP-MYTHiC Trial and Registry - CardioMyoPathy With MYocarditis THerapy With Colchicine","Single-blinded Randomized Investigator-initiated Controlled Trial to Assess the Efficacy of Colchicine to Treat Patients With Cardiomyopathy With Myocarditis (Chronic Inflammatory Cardiomyopathy)","CMP-MYTHiC","Inclusion Criteria Trial and Registry:\n\n* Males and females with Infl-CMP associated with VA (including high PVC burden), reduced LVEF, or significantly increased levels of natriuretic peptides.\n* Patients of 18 years or older\n* Evidence of myocardial inflammation on CMRI (using 2018 Lake Louis criteria) or FDG-PET performed in the 3 months before randomization to be included in the trial OR in the last 12 months before for the registry.\n* Presence of any of the following characteristics and if symptoms have been present for more than 1 month:\n* Mono-morphic or polymorphic PVC burden of ≥3000 in 24 hours, or NSVTs (defined as \\>3 more consecutive beat lasting \\\u003C30 seconds) or evidence of sustained ventricular tachycardias (SVT).\n* Reduced LVEF on echocardiogram (\\\u003C50%) or on CMRI (\\\u003C60%)-. Increased N-terminal pro-B-type natriuretic peptide (NT- proBNP) concentration of 1000 pg\u002FmL or more, or a B-type natriuretic peptide (BNP) concentration of 200 pg\u002FmL or more\n* Persistence of increased high-sensitivity troponin levels above the upper reference limit (URL) after at least 2 months from the first assessment and at least a mono-morphic or polymorphic PVC burden of ≥1000 in 24 hours.\n\nExclusion Criteria Registry:\n\n* Proven history of myocardial infarction with evidence of ischemic scar on echocardiogram or CMRI,\n* Significant flow-limiting coronary artery disease (stenosis above 50%) on invasive coronary angiography or computed tomography (CT) coronary angiography,\n* Cardiomyopathy attributed to toxins such as alcohol and illicit drugs, or to specific causes (i.e. amyloidosis or hypertrophic cardiomyopathy)\n* Known systemic autoimmune disorder (the exception will be for patients with systemic autoimmune disease or isolated cardiac sarcoidosis with a family history of cardiomyopathy, myocarditis, or arrhythmias, where overlap between an autoimmune event and a genetic background can occur). These patients will undergo genetic tests. Patients with autoimmune systemic disorders and isolated cardiac sarcoidosis with positive genetic tests for MCVG will be included in the registry.\n* Previous history of cardiac surgery for instance correction of congenital heart disease or a valve repair\u002Freplacement\n* Known chronic infective disease, such as HIV infection or tuberculosis\n* Participants involved in another clinical trial, defined by the participation in a clinical trial in which an investigational drug was administered in the 30 days prior to screening, or 5 half-lives of the study drug, whichever is longer;\n* Any other significant disease or disorder which (expected life expectancy \\\u003C12 months), in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial or the participant's ability to participate in the trial.\n\nExclusion Criteria Trial :\n\n* Proven history of myocardial infarction with evidence of ischemic scar on echocardiogram or CMRI,\n* Significant flow-limiting coronary artery disease (stenosis above 50%) on invasive coronary angiography or computed tomography (CT) coronary angiography,\n* Cardiomyopathy attributed to toxins such as alcohol and illicit drugs, or to specific causes (i.e. amyloidosis or hypertrophic cardiomyopathy)\n* Known systemic autoimmune disorder (the exception will be for patients with systemic autoimmune disease or isolated cardiac sarcoidosis with a family history of cardiomyopathy, myocarditis, or arrhythmias, where overlap between an autoimmune event and a genetic background can occur). These patients will undergo genetic tests. Patients with autoimmune systemic disorders and isolated cardiac sarcoidosis with positive genetic tests for MCVG will be included in the registry.\n* Previous history of cardiac surgery for instance correction of congenital heart disease or a valve repair\u002Freplacement\n* Known chronic infective disease, such as HIV infection or tuberculosis\n* Participants involved in another clinical trial, defined by the participation in a clinical trial in which an investigational drug was administered in the 30 days prior to screening, or 5 half-lives of the study drug, whichever is longer;\n* Any other significant disease or disorder which (expected life expectancy \\\u003C12 months), in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial or the participant's ability to participate in the trial.\n* Women with childbearing potential (this exclusion criterion is due to insufficient human information regarding the embryofoetal risk with colchicine)\n* Current symptomatic atrial arrhythmias (including persistent atrial fibrillation) associated with LV dysfunction,\n* Advance heart failure (NYHA III or need for inotropes including levosimendan), or recurrent VA despite previous catheter ablation,\n* Known systemic autoimmune disorder or other conditions at the time of randomization where immunosuppression is assumed useful (i.e. cardiac sarcoidosis),\n* Patients already on chronic immunosuppressive therapies (including colchicine) or in whom immunosuppressive therapy is deemed necessary\n* Contraindication to colchicine, including allergies to this medication and its excipients (i.e., lactose and sucrose),\n* Impaired renal function (eGFR\\\u003C30 ml\u002Fmin\u002F1.73m2),\n* Known history of hepatic cirrhosis or transaminase levels at baseline \\> x3-fold the URL\n* Patients with peripheral eosinophilia (eosinophil count \\>10% of the leukocytes) or known hypereosinophilic syndrome at the time of randomization.\n* Severe gastrointestinal insufficiency (for instance, malabsorption syndrome, severe chronic diarrhea)\n* Women during breastfeeding",{"count":114,"type":20},80,[116],"PHASE3","Two-parallel groups randomized, single-blinded, multi-center phase III controlled trial in patients with chronic inflammatory cardiomyopathy to assess the efficacy of colchicine and associated prospective registry to assess the prognostic value of positive genetic testing in this population.",[119,120,121,122,26],"Cardiomyopathies","Myocarditis","Inflammatory Cardiomyopathy","Heart Failure",[124,125,126,127,128,129,130],"treatment","trial","colchicine","registry","inflammation","outcome","genetic testing","2026-04-15",{"date":133,"type":36},"2026-04-20",{"date":135,"type":36},"2023-11-14",{"date":137,"type":20},"2028-05-02",{"name":139,"class":82},"Niguarda Hospital",10,{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":145,"acronym":146,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":148,"targetDuration":4,"studyType":93,"phases":4,"briefSummary":150,"conditions":151,"keywords":4,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":160,"leadSponsor":162,"locationsCount":4},"100630712","rhythm-and-myocardial-function-relationship-evaluation-in-heart-diseases-100630712","NCT07491237","RHYthm and Myocardial Function Relationship Evaluation in Heart Diseases","RHYME-HD","Inclusion Criteria:\n\n* Only patients aged \\> 18 years with a history of arrhythmia warranting non-pharmacological treatment according to the guidelines will be selected.\n* Collection of informed consent for the prospective cohort.\n* For the retrospective cohort, the Promoter has carried out a Data Protection Impact Assessment (DPIA), which ascertained the adequacy of the technical and organisational measures adopted to ensure the protection of the fundamental rights and freedoms of data subjects, in accordance with Article 89 of Regulation (EU) 2016\u002F679 and the guidelines of the Data Protection Authority. Data processing will be limited to the purposes of the study and conducted in accordance with the principles of minimisation, pseudonymisation and security, in compliance with the guarantees defined by the Data Protection Authority.\n\nExclusion Criteria:\n\n* Patients who, upon initial assessment at our centre, do not present arrhythmias that would indicate non-pharmacological treatment.\n* Patients for whom it is not possible to obtain adequate medical history and\u002For follow-up through medical examination or telephone consultation.\n* Refusal to give informed consent to participate in the study.",{"count":149,"type":20},253,"Arrhythmias are widespread among the global population. Although they can occur in healthy hearts, they are often the manifestation of a hereditary or acquired heart muscle disease, and may be the cause or, more often than not, the consequence.\n\nIn recent decades, with advances in medical knowledge and technology, non-pharmacological therapies for arrhythmias have become increasingly popular. These fall into two broad categories: therapies aimed at electrostimulation and those aimed at ablation of arrhythmias.\n\nThe selection of patients eligible for these procedures is essential for the effectiveness of the therapy, the reduction of complications and the optimisation of resources.\n\nNot all patients, even those selected according to guidelines, respond equally to the chosen therapy. Other patients, due to their clinical\u002FECG characteristics, do not have clear indications and remain in a borderline area where the class of evidence and\u002For recommendation of the guidelines is less stringent. Still others develop recurrences or complications during follow-up that require further intervention.\n\nIn this context, it is essential in the study of these patients not only to use standard instrumental examinations, such as echocardiograms, Holter ECGs and stress tests (simple and cardiopulmonary), but also and above all to use advanced imaging methods (STE, 3D echo, MRI, CT, PET-CT) and remote monitoring tools that integrate diagnostic algorithms managed by artificial intelligence.\n\nIn light of these considerations, our project consists of conducting an observational study that includes all patients with arrhythmias who are candidates for electrostimulation and\u002For ablation procedures at the Arrhythmology Unit and\u002For followed up at the Arrhythmology Clinic of our Polyclinic, in order to assess the clinical and\u002For imaging characteristics associated with a worse prognosis in this population, in terms of response to therapy and development of complications. Our main aim is to identify, within the above-mentioned population, the subgroups of responder patients versus non-responder patients, i.e. those with a worse prognosis , who deserve greater attention and more frequent follow-up.",[152,153,154,155,26,122,119],"Arrhythmia","Cardiomyopathy, Dilated","Systolic Dysfunction","Atrial Fibrillation","2026-03-18",{"date":158,"type":36},"2026-03-24",{"date":131,"type":20},{"date":161,"type":20},"2031-12-31",{"name":163,"class":82},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":168,"acronym":169,"eligibilityCriteria":170,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":171,"enrollmentInfo":172,"targetDuration":4,"studyType":21,"phases":174,"briefSummary":175,"conditions":176,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":83},"100521616","emergency-resuscitative-endovascular-balloon-occlusion-of-the-aorta-in-out-of-hospital-cardiac-arrest-100521616","NCT06071910","Emergency Resuscitative Endovascular Balloon Occlusion of the Aorta in Out of Hospital Cardiac Arrest","ERICA-ARREST","Inclusion criteria\n\n* Non-Traumatic OHCA in patients within the East of England area AND with a East Anglian Air Ambulance (EAAA) REBOA team in attendance\n* Patients below or equal to 80yrs of age and above or equal to 18yrs of age, according to available information\u002Festimate at scene\n* No flow \\\u003C10 mins from data available (i.e. total period in OHCA with no CPR)\n* In cardiac arrest (with no sustained ROSC) on arrival of the EAAA REBOA team\n\nExclusion criteria\n\n* Patients aged less than 18 or above 80 years\n* Known terminal illness\n* Multiple severe co-morbidities\n* Traumatic Cardiac Arrest (TCA)\n* Inability to deploy mechanical CPR (e.g. LUCAS Device)\n* Pregnancy, obvious or suspected","80 Years",{"count":173,"type":20},40,[23],"This study will assess the feasibility of performing pre-hospital resuscitative endovascular balloon occlusion of the aorta (REBOA) as an adjunct to conventional Advanced Life Support (ALS) in patients suffering from non-traumatic out of hospital cardiac arrest (OHCA). As well as providing valuable insights into the technical feasibility of performing this procedure as part of a resuscitation attempt, the study will also document the beneficial physiological effects of REBOA in this group of patients.",[177,178,179,27,26,180],"Out-Of-Hospital Cardiac Arrest","Cardiac Arrest","Cardiac Arrhythmia","Pulseless Electrical Activity","2026-02-26",{"date":183,"type":36},"2026-03-02",{"date":185,"type":36},"2024-06-04",{"date":187,"type":20},"2026-12-31",{"name":189,"class":82},"Queen Mary University of London",{"id":191,"slug":192,"hasResults":11,"nctId":193,"briefTitle":194,"officialTitle":194,"acronym":195,"eligibilityCriteria":196,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":197,"targetDuration":4,"studyType":21,"phases":198,"briefSummary":199,"conditions":200,"keywords":202,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":83},"100543828","radiotherapy-vs-catheter-ablation-for-ventricular-tachycardia-in-structural-heart-disease-100543828","NCT06360939","Radiotherapy vs Catheter Ablation for Ventricular Tachycardia in Structural Heart Disease","RadioAblate-VT","Inclusion Criteria:\n\n1. Structural heart disease (including ischaemic cardiomyopathy , non-ischaemic cardiomyopathy or congenital heart disease and defined as any one of\n\n   1. segmental or global decreased ventricular wall motion as defined by TTE, CT or cMRI\n   2. myocardial hypertrophy\n   3. myocardial scar (evidenced by late gadolinium enhancement on cMRI, wall thinning on cardiac CT, low voltage on electrophysiological study or abnormal intracardiac echocardiography)\n2. Recurrent monomorphic VT which can include\n\n   1. at least one episode of VT treated by ICD and\u002For\n   2. sustained VT (lasting \\>30s) and\u002For\n   3. inducible sustained VT on invasive electrophysiological study (EPS) or non-invasive programmed stimulation (NIPS)\n3. PAINESD score of ≥9 points and\u002For at least moderate risk of VT recurrence or death as defined by the I-VT score. Both are validated tools used clinically to identify patient at high risk of VT recurrence and\u002For mortality after CA.\n\nExclusion Criteria:\n\n1. Age \\\u003C 18 years\n2. Life expectancy \\\u003C 3 months\n3. Catheter ablation deemed futile or with prohibitive risk by cardiac electrophysiologist.\n4. Unwilling or unable to provide consent\n5. Known cardiac channelopathies (e.g. Catecholaminergic polymorphic ventricular tachycardia (CPVT), long- or short QT syndrome, Brugada syndrome)\n6. Contraindications to radiotherapy as deemed by referring physician and\u002For radiation oncologist\n7. Pregnancy or breast feeding",{"count":68,"type":20},[23],"The goal of this randomized clinical trial is to test the efficacy of stereotactic body radiation therapy (SBRT) in treating ventricular tachycardia (VT) in patients with advanced structural heart disease. The main questions it aims to answer are:\n\n* What is the efficacy of SBRT compared to catheter ablation (CA) in achieving a ≥ 75% reduction in VT burden at 6 months\n* What is the comparable safety profile of SBRT vs CA Researchers will compare SBRT and CA (standard of care).",[28,119,201,26],"Arrhythmias, Cardiac",[203,204,205,206],"catheter ablation","stereotactic body radiation therapy","non invasive","radioablation","2026-02-15",{"date":209,"type":36},"2026-02-18",{"date":211,"type":36},"2025-11-03",{"date":213,"type":20},"2027-12-20",{"name":215,"class":82},"Western Sydney Local Health District",{"id":217,"slug":218,"hasResults":11,"nctId":219,"briefTitle":220,"officialTitle":221,"acronym":222,"eligibilityCriteria":223,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":224,"targetDuration":226,"studyType":93,"phases":4,"briefSummary":227,"conditions":228,"keywords":240,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":256,"locationsCount":83},"100608041","polish-registry-of-cardioneuroablation-and-cardioneuromodulation-100608041","NCT07196397","POLish Registry of CArdioneuroablation and CArdioneuromodulation","POL-CA Registry: Multicenter Observational Study of Neuromodulatory Procedures in Cardiovascular Autonomic Dysfunction Syndromes","POL-CA","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Diagnosis of at least one of the following conditions:\n\n  * Inappropriate sinus tachycardia (IST)\n  * Postural orthostatic tachycardia syndrome (POTS)\n  * Vasovagal syncope (VVS)\n  * Cardioinhibitory carotid sinus syndrome (CSS)\n  * Symptomatic sinus bradycardia or functional AV block\n  * Orthostatic hypotension (OH)\n* History of recurrent autonomic symptoms (e.g., syncope, bradycardia, palpitations, orthostatic intolerance)\n* Undergoing or previously underwent interventional treatment affecting cardiac autonomic innervation (e.g., cardioneuroablation, SN-sparing ablation, cardiac sympathetic denervation)\n* Provided written informed consent (for prospective arm)\n\nExclusion Criteria:\n\n* Structural heart disease requiring surgical intervention\n* Permanent pacemaker or ICD implanted prior to enrollment\n* Inability to complete follow-up assessments or questionnaires\n* Severe psychiatric comorbidities impairing participation\n* Participation in another interventional clinical trial",{"count":225,"type":20},1000,"3 Years","The multicentre observational study POL-CA involves a wide spectrum of patients with a history of syncopy. The study recruits patients with diagnosed vasovagal syndrome, cardioinhibitory carotid sinus syndrome, symptomatic sinus bradycardia or atrioventricular block, postural orthostatic tachycardia syndrome, orthostatic hypotension, and inappropriate sinus tachycardia syndrome. This is an observational, controlled study with retrospective, clinical data analysis of previously treated patients and the analysis of syncopal patients prospectively recruited into the study. The aim of the POL-CA registry is to create a platform for physicians to record treatment data for patients undergoing procedures that affect innervation or modify cardiovascular reflexes (cardioneuroablation, cardioneuromodulation) in order to provide a multicentre summary of population characteristics and treatment outcomes based on a standardized POL-CA questionnaire and methodology for various arrhythmias.",[229,230,231,232,233,234,235,236,26,237,238,239],"Vasovagal Syndrome VVS","Cardioinhibitory Carotid Sinus Syndrome CSS","Symptomatic Sinus Bradycardia SB or Atrioventricular Block AV","Postural Orthostatic Tachycardia Syndrome POTS","Orthostatic Hypotension","Inappropriate Sinus Tachycardia Syndrome IST","Vasospastic Angina","Microvascular Angina","Raynaud Phenomena","Autonomic Dysfunction","Autonomic Diseases",[241,242,243,203,244,245,246,247,248,249],"cardioneuroablation","cardiac sympathetic denervation","sinoatrial node sparing hybrid ablation","neural stimulation","cardioneuromodulation","percutaneus stellate ganglion blockage","cardiac rehabilitation","cardiovascular autonomic tests","syncope","2025-09-21",{"date":252,"type":36},"2025-09-29",{"date":254,"type":36},"2024-11-21",{"date":161,"type":20},{"name":257,"class":258},"SABAMED Medical Center Ltd.","NETWORK",{"id":260,"slug":261,"hasResults":11,"nctId":262,"briefTitle":263,"officialTitle":263,"acronym":264,"eligibilityCriteria":265,"healthyVolunteers":266,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":267,"targetDuration":4,"studyType":93,"phases":4,"briefSummary":269,"conditions":270,"keywords":272,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":279,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":285,"locationsCount":83},"100503033","development-of-an-artificial-intelligence-algorithm-to-detect-pathological-repolarization-disorders-on-the-ecg-and-the-risk-of-ventricular-arrhythmias-100503033","NCT05829993","Development of an Artificial Intelligence Algorithm to Detect Pathological Repolarization Disorders on the ECG and the Risk of Ventricular Arrhythmias","DEEPECG4U","Inclusion Criteria:\n\n* Age ≥ 18\n* Patients or subjects taken care in recruiting centres for which an ECG is indicated\n* No opposition to participation in the study\n\nExclusion Criteria:\n\n* Medical contraindication for ECG\n* Subjects with pacemaker-driven QRS",true,{"count":268,"type":20},5000,"Torsades de Pointes (TdP) are potentially fatal ventricular arrhythmias that are promoted by prolonged ventricular repolarization (Long QT, LQT). The different forms of LQT result from inhibition of cardiac potassium currents (IKr and IKs) or activation of a late sodium current (INaL). These alterations may be either congenital (3 types: cLQT-1: IKs, cLQT-2: IKr, cLQT-3: INaL) or drug-induced (diLQT, via inhibition of IKr).\n\nMore than 100 medications have received marketing authorization despite a known risk of TdP, due to a favorable benefit-risk ratio (e.g., hydroxychloroquine).\n\nQTc, which represents the duration of ventricular repolarization (in milliseconds) - defined as the time from the beginning of the QRS complex to the end of the T wave, corrected for heart rate - is prolonged in all forms of LQT.\n\nSpecific T-wave abnormalities, depending on the altered ion currents, have been described and can help differentiate the various types of congenital or drug-induced LQT.\n\nHowever, screening for LQT and TdP risk, both at the individual and population levels, currently relies mainly on isolated QTc evaluation and genetic testing, which often takes considerable time to return.\n\nThus, limiting ECG analysis to QTc measurement alone offers low predictive value, as the ECG contains a wealth of additional information beyond a single interval.\n\nThe investigator recently demonstrated that artificial intelligence (AI)-based ECG analysis using deep-learning convolutional neural networks can detect more discriminative features of the ECG for predicting the type of LQT and the risk of TdP, going beyond QTc alone.\n\nUsing these techniques, the investigator developed a model with probabilistic modules capable of: predicting TdP risk, identifying LQT subtypes (scores ranging from 0 to 100%), and quantitatively measuring ECG parameters such as QTc, heart rate, PR, and QRS duration.\n\nThe objective of this project is to prospectively validate our model in real-world conditions across various departments within AP-HP, for:\n\nAutomatic measurement of QTc, and Identification and classification of LQT types and TdP risk.",[271,26],"Cardiac Disease",[273,274,275,276,277],"Artificial intelligence","ECG","Repolarization","QT","Ventricular arrhythmias","2025-07-28",{"date":280,"type":36},"2025-07-31",{"date":282,"type":36},"2023-11-28",{"date":284,"type":20},"2027-06-28",{"name":286,"class":82},"Assistance Publique - Hôpitaux de Paris",{"id":288,"slug":289,"hasResults":11,"nctId":290,"briefTitle":291,"officialTitle":292,"acronym":293,"eligibilityCriteria":294,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":295,"enrollmentInfo":296,"targetDuration":4,"studyType":93,"phases":4,"briefSummary":298,"conditions":299,"keywords":4,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":302,"lastUpdatePostDateStruct":303,"startDateStruct":305,"completionDateStruct":307,"leadSponsor":309,"locationsCount":4},"100595485","recurrent-ventricular-arrythmias-in-icu-100595485","NCT07033065","Recurrent Ventricular Arrythmias in ICU","In Hospital and Long Term Outcomes After Recurrent Ventricular Arrythmias","ElectStorm","Inclusion Criteria:\n\nAll ventricular arrythmias admitted in ICU -\n\nExclusion Criteria:\n\n\\-","90 Years",{"count":297,"type":20},300,"Electrical storm (ES) is a life-threatening syndrome defined by the recurrence of ventricular arrythmias.\n\nES is also represented by a wide spectrum of clinical situations ranging from recurrent monomorphic VT reduced by anti-tachycardia pacing (ATP) in relatively stable patients to recurrent VF in hemodynamically unstable patients.\n\nThus, the purpose of this study was to assess the incidence and predictors of long term mortality following hospitalization in the intensive care unit for ES, in a large retrospective multicentric study.",[26,300,301],"Cardiogenic Shock","Electrical Storm","2025-06-13",{"date":304,"type":36},"2025-06-24",{"date":306,"type":20},"2025-07-01",{"date":308,"type":20},"2025-10-15",{"name":310,"class":82},"Central Hospital, Nancy, France",{"id":312,"slug":313,"hasResults":11,"nctId":314,"briefTitle":315,"officialTitle":316,"acronym":317,"eligibilityCriteria":318,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":319,"targetDuration":321,"studyType":93,"phases":4,"briefSummary":322,"conditions":323,"keywords":324,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":329,"lastUpdatePostDateStruct":330,"startDateStruct":332,"completionDateStruct":334,"leadSponsor":336,"locationsCount":83},"100493629","bipolar-radio-frequency-ablation-after-standard-unipolar-approach---prospective-registry-100493629","NCT05707637","Bipolar Radio-frequency Ablation After Standard Unipolar Approach - Prospective Registry.","Bipolar Radio-frequency Ablation After Standard Unipolar Approach for Ventricular Arrhythmias Originating From the Base of the Heart. The BiUniVA Prospective Registry","BiUniVA","Inclusion Criteria:\n\n1. Baseline Holter ECG before initial unipolar ablation within 6 months prior to the procedure, performed without antiarrhythmic drugs (beta-blockers allowed).\n2. Initial unipolar ablation of VA originating from the base of the heart (R in II, III and aVF) performed according to the standard scheme which includes detailed measurements of EP parameters at each examined and\u002For ablated site and inspection of all three regions (RVOT with PA, GCV and LVOT\u002FAoCusps\u002FAMC\u002FMA) in cases with unsatisfactory EP parameters or failed ablation at first or second site.\n3. Typical indications for ablation: a. \\> 10 000 PVC in 24-hour Holter ECG or b. \\> 10% PVC in 24-hour Holter ECG or c. less frequent but symptomatic PVC or d. at least 3 episodes symptomatic non-sustained ventricular tachycardia (nsVT) (\\>3 QRS evolutions) in Holter ECG, regardless of the amount of PVC or e. sustained ventricular tachycardia (sVT), regardless of nsVT or PVC\n4. Written informed consent\n\nExclusion Criteria:\n\n1. History of \\> 1 unipolar ablation for VA originating at the base of the heart\n2. Lack of properly acquired EP parameters during baseline unipolar ablation\n3. Lack of baseline Holter ECG performed \\\u003C 6 months prior to initial unipolar ablation\n4. Absence of typical indication for ablation\n5. Lack of written informed consent for participation in the study",{"count":320,"type":20},100,"1 Month","Treatment of ventricular arrhythmias (VA) originating at the base of the heart may be challenging. Unipolar radio-frequency (RF) ablation is a standard approach to treat VA, however, it fails in 10 to 75% of patients, depending on the localization of VA. The main reason for unipolar ablation failure is the intramural location of the source of VA. In such patients, bipolar ablation may occur effective. However, there are no prospective studies or registries on consecutive patients wilt failed unipolar ablation, therefore, the proportion of candidates for bipolar ablation after failed unipolar approach is not known. Also, invasive electrophysiological parameters associated with successful unipolar and bipolar ablation have not been well established. It has been hypothesised that (1) bipolar ablation fails in 12-75% (mean 30%) of consecutive patients and these patients are candidates for bipolar ablation, (2) local ventricular signal precocity \\> 20 ms, unipolar signal without R wave and pace mapping 12\u002F12 predict effective unipolar ablation but not bipolar ablation, (3) morphology of VA from surface ECG can identify patients with possible intramural localization, and (4) successful ablation results in improvement of quality of life (QoL).\n\nAims:\n\n1. To assess how many patients after failed unipolar ablation need redo procedure with bipolar ablation (primary end-point)\n2. To assess which intraprocedural electrophysiological parameters predict success during standard unipolar ablation (secondary endpoint)\n3. To assess short term efficacy of bipolar ablation (secondary endpoint)\n4. To assess one-month efficacy of bipolar ablation (secondary endpoint)\n5. To assess which intraprocedural electrophysiological parameters predict success during redo bipolar ablation (secondary endpoint)\n6. To evaluate the performance of ECG-based algorithms in predicting the localization \u002F origin of VA, especially of transmural origin (secondary endpoint)\n7. To assess the effects of ablation on QoL (secondary endpoint)Methods. The study group consists of all consecutive patients who underwent unipolar ablation of VA originating from the base of the heart in the Grochowski Hospital and collaborating centres. All these patients are referred to Grochowski Hospital for further follow-up and treatment if needed, including bipolar ablation if initial unipolar approach failed. In all patients acute and one-month efficacy of unipolar and bipolar ablation is assessed.",[26],[325,326,327,328],"ventricular arrhythmia","unipolar ablation","bipolar ablation","base of the heart","2025-05-10",{"date":331,"type":36},"2025-05-13",{"date":333,"type":36},"2022-11-02",{"date":335,"type":20},"2026-02-01",{"name":337,"class":82},"Centre of Postgraduate Medical Education",{"id":339,"slug":340,"hasResults":11,"nctId":341,"briefTitle":342,"officialTitle":343,"acronym":344,"eligibilityCriteria":345,"healthyVolunteers":266,"sex":16,"minAge":346,"maxAge":171,"enrollmentInfo":347,"targetDuration":4,"studyType":93,"phases":4,"briefSummary":349,"conditions":350,"keywords":351,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":355,"startDateStruct":357,"completionDateStruct":359,"leadSponsor":361,"locationsCount":83},"100584463","geam-study-aims-at-assessing-the-role-of-genetic-testing-in-patients-with-arrhythmic-myocarditis-100584463","NCT06889662","GEAM Study Aims At Assessing the Role of Genetic Testing in Patients with Arrhythmic Myocarditis.","GEAM: Yield of GEnetic Testing in Arrhythmic Myocarditis","GEAM","Inclusion Criteria:\n\nPatients with ventricular arrhythmias (VA+) and without (VA-)\n\n* Diagnosis of myocarditis proven by EMB (ESC criteria) and\u002For CMR (updated Lake Louise criteria)\n* Age ≥ 10 years\n* Baseline ECG telemonitoring\n* Written informed consent Healthy controls\n* Provided a negative known history of myocarditis\n* The sample must have been biobanked as part of the study IMMUNORADAR\n\nExclusion Criteria:\n\nPatients with ventricular arrhythmias (VA+) and without (VA-)\n\n* Obstructive coronary artery disease, or lack of coronary angiography\u002Fcomputed tomography (CT) scan in patients \\>40 years.\n* Absent informed consent.","10 Years",{"count":348,"type":20},262,"This study aims to answer multiple unsolved questions in the field of arrhythmic myocarditis.\n\n* Improving the diagnostic work-up. While endomyocardial biopsy (EMB) and cardiac magnetic resonance (CMR) constitute the gold standard diagnostic techniques for myocarditis, the role of genetic testing is still unclear. Identifying the subset of patients with CGVs, will contribute to justifying the application of genetic testing in myocarditis.\n* Generating models for risk prediction. Outcomes and arrhythmic risk stratification remain uncertain for myocarditis. Based on an advanced multimodal work-up, multiparametric risk scores may be created and subsequently validated, in order to predict the arrhythmic risk of specific myocarditis, especially in the case of CGVs.\n* Identifying disease-specific and genotype-specific signatures. Genotype-phenotype associations are expected to benefit from a multimodal and multiparametric approach, in order to allow etiology-specific features in arrhythmic myocarditis. Most of the current signatures are limited to combined EMB-CMR studies. Signatures would likely benefit from implementing additional parameters, including arrhythmia features and myocardial inflammatory status.\n* Tailoring treatment strategies. Transcriptional analysis will identify overexpressed genes associated with myocarditis and arrhythmias, representing a possible therapeutic target. A multimodal and multidisciplinary model will integrate phenotype, genotype, and transcriptional profile for a personalized treatment.",[120,26],[352,277,353],"Arrhythmogenic cardiomyopathy","Myocardial inflammation","2025-03-19",{"date":356,"type":36},"2025-03-21",{"date":358,"type":36},"2025-02-25",{"date":360,"type":20},"2027-12-01",{"name":362,"class":82},"Scientific Institute San Raffaele",{"id":364,"slug":365,"hasResults":11,"nctId":366,"briefTitle":367,"officialTitle":368,"acronym":4,"eligibilityCriteria":369,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":370,"targetDuration":4,"studyType":93,"phases":4,"briefSummary":371,"conditions":372,"keywords":380,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":384,"lastUpdatePostDateStruct":385,"startDateStruct":387,"completionDateStruct":389,"leadSponsor":391,"locationsCount":83},"100562965","cardiovascular-multimodality-imaging-study-100562965","NCT06610019","Cardiovascular Multimodality Imaging Study","Risk Stratification of Ischemic and Non-ischemic Cardiomyopathies in Racial and Ethnic Minority Groups in the Bronx - Cardiovascular Multimodality Imaging Study","Inclusion Criteria:\n\n* Any adult patient (18 years or older) referred for a cardiovascular magnetic resonance (CMR) imaging study in the Montefiore Health System\n\nExclusion Criteria:\n\n* Any patient who does not meet above criteria",{"count":268,"type":20},"Determining the etiology of cardiomyopathy is of high clinical importance for optimal treatment strategy and prediction of prognosis. There is increased risk for cardiovascular disease and higher propensity for cardiovascular related mortality among Black and non-Hispanic White patients. Recently, advanced cardiac imaging has become a vital tool in diagnosis and risk stratification of cardiovascular disease. Very limited data is available on the prevalence and characteristics of different cardiovascular diseases in Hispanic and African American minority groups, therefore, studying different racial and ethnic minority groups in the Bronx population is an exceptionally valuable source to determine the prevalence of cardiomyopathies among minority groups along with study survival in this population. This study aims to determine the etiology of cardiovascular disease in a diverse patient population by utilizing various cardiovascular imaging modalities, with a focus on cardiac magnetic resonance (CMR) imaging and to develop risk stratification models by applying advanced cardiovascular imaging markers.",[373,119,374,375,376,377,378,379,26,122],"Non-ischemic Cardiomyopathy","Hypertrophic Cardiomyopathy","Right Ventricular Arrhythmogenic Cardiomyopathy","Cardiac Amyloidosis","Anderson Fabry Disease","Sarcoidosis","Cancer Therapy-related Cardiac Dysfunction",[381,382,383],"Cardiovascular Mortalities","Cardiomagnetic Resonance (CMR) Imaging","Prospective","2025-02-12",{"date":386,"type":36},"2025-02-14",{"date":388,"type":36},"2023-05-01",{"date":390,"type":20},"2031-12",{"name":392,"class":82},"Montefiore Medical Center",{"id":394,"slug":395,"hasResults":11,"nctId":396,"briefTitle":397,"officialTitle":398,"acronym":399,"eligibilityCriteria":400,"healthyVolunteers":11,"sex":16,"minAge":401,"maxAge":4,"enrollmentInfo":402,"targetDuration":404,"studyType":93,"phases":4,"briefSummary":405,"conditions":406,"keywords":408,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":414,"lastUpdatePostDateStruct":415,"startDateStruct":416,"completionDateStruct":418,"leadSponsor":420,"locationsCount":83},"100437444","the-multicenter-cardiology-monitoring-platform-registry-100437444","NCT04976348","The Multicenter Cardiology Monitoring Platform Registry","The Multicenter Cardiology Monitoring Platform Registry (mCMP-registry)","mCMPregistry","Inclusion Criteria:\n\n* Referred to the cardiology or genetic department for heart failure like symptoms (as stated in the ESC 2016 Guidelines(3)) or for cardiac\u002Fcardiogenetic screening;\n* Age ≥16 years.\n\nExclusion Criteria:\n\n* Unwillingness to participate or unable to give written informed consent (e.g. due to language barriers or severe intellectual disability).","16 Years",{"count":403,"type":20},40000,"15 Years","The multicenter Cardiology Monitoring Platform registry (mCMP-registry) is a prospective observational registry including multi-omics (diagnostic) measurements performed as part of routine clinical care, bio-banking (optional), and yearly questionnaires (optional).\n\nIt's objective is to optimize (early) diagnosis and risk-stratification of (early) cardiovascular diseases, specifically cardiomyopathy phenotypes, arrhythmias, and coronary artery disease, and to create a better understanding of underlying pathophysiological processes.",[122,119,155,26,407,28],"Coronary Artery Disease",[409,127,410,411,412,413],"heart failure","cardiomyopathy","atrial fibrillation","ventricular tachycardia","coronary artery disease","2024-11-19",{"date":254,"type":36},{"date":417,"type":36},"2021-07-01",{"date":419,"type":20},"2051-12",{"name":421,"class":82},"Maastricht University Medical Center",{"id":423,"slug":424,"hasResults":11,"nctId":425,"briefTitle":426,"officialTitle":426,"acronym":427,"eligibilityCriteria":428,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":429,"targetDuration":346,"studyType":93,"phases":4,"briefSummary":430,"conditions":431,"keywords":436,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":452,"lastUpdatePostDateStruct":453,"startDateStruct":455,"completionDateStruct":457,"leadSponsor":459,"locationsCount":83},"100402555","role-of-endomyocardial-biopsy-and-aetiology-based-treatment-in-patients-with-inflammatory-heart-disease-in-arrhythmic-and-non-arrhythmic-clinical-presentations-an-integrated-approach-for-the-optimal-diagnostic-and-therapeutic-management-100402555","NCT04521790","Role of Endomyocardial Biopsy and Aetiology-based Treatment in Patients With Inflammatory Heart Disease in Arrhythmic and Non-arrhythmic Clinical Presentations: an Integrated Approach for the Optimal Diagnostic and Therapeutic Management","MYOCAR","Inclusion Criteria:\n\n* Written informed consent.\n* Age ≥ 18 years.\n* Clinically suspected myocarditis.\n* Enrollment performed by one of the participating Centers.\n\nExclusion Criteria:\n\n* Absence of written informed consent.\n* Age \\\u003C 18 years (paediatric population).",{"count":225,"type":20},"Myocarditis is a complex inflammatory disease, usually occurring secondary to viral infections, autoimmune processes or toxic agents. Clinical presentations are multiple, including chest-pain, heart failure and a broad spectrum of arrhythmias. In turn, outcome is largely unpredictable, ranging from mild self-limiting disease, to chronic stage and progressive evolution towards dilated cardiomyopathy, to rapid adverse outcome in fulminant forms. Subsequently, myocarditis is often underdiagnosed and undertreated, and optimal diagnostic and therapeutic strategies are still to be defined. This study, both retrospective and prospective, originally single-center and subsequently upgraded to multicenter, aims at answering multiple questions about myocarditis, with special attention to its arrhythmic manifestations.\n\n1. Optimal diagnostic workflow is still to be defined. In fact, although endomyocardial biopsy (EMB) is still the diagnostic gold standard, especially for aetiology identification, it is an invasive technique. Furthermore, it may lack sensitivity because of sampling errors. By converse, modern imaging techniques - cardiac magnetic resonance (CMR) in particular - have been proposed as alternative or complementary diagnostic tool in inflammatory heart disease. Other noninvasive diagnostic techniques, like delayed-enhanced CT (DECT) scan or position emission tomography (PET) scan, are under investigation.\n2. Biomarkers to identify myocarditis aetiology, predisposition, prognosis and response to treatment are still to be defined.\n3. Arrhythmic myocarditis is largely underdiagnosed and uninvestigated. Importantly, myocarditis presenting with arrhythmias requires specific diagnostic, prognostic and therapeutic considerations. At the group leader hospital, which is an international referral center for ventricular arrhythmias management and ablation, a relevant number of patients with unexplained arrhythmias had myocarditis as underlying aetiology. The experience of a dedicated third-level center is going to be shared with other centers, to considerably improve knowledge and management of arrhythmic myocarditis.\n4. The role of CMR, as well as alternative noninvasive imaging techniques, in defining myocarditis healing is a relevant issue. In particular, optimal timing for follow-up diagnostic reassessment is still to be defined, in patients with myocarditis at different inflammatory stages, either with or without aetiology-dependent treatment.\n5. Uniformly-designed studies are lacking, to compare myocarditis among different patient subgroups, differing by variables like: clinical presentations, myocarditis stage, associated cardiac or extra-cardiac diseases, aetiology-based treatment, associated arrhythmic manifestations, diagnostic workup, and devices or ablation treatment.",[120,26,121,432,433,152,119,434,435],"Genetic Predisposition","Autoimmunity","Immunosuppression","Catheter Ablation",[120,277,437,438,439,440,441,442,443,444,445,446,447,448,449,450,451],"Arrhythmias","Arrhythmogenic inflammatory cardiomyopathy","Endomyocardial biopsy","Cardiac magnetic resonance","Ablation","Positron emission tomography","Cardiac imaging","Electroanatomical mapping","Immunosuppressive therapy","Arrhythmic risk stratification","Genetic predisposition","Environment","Implantable cardioverter defibrillator","Implantable loop recorder","Multicenter","2024-09-07",{"date":454,"type":36},"2024-09-19",{"date":456,"type":36},"2018-01-30",{"date":458,"type":20},"2035-12-31",{"name":362,"class":82},{"id":461,"slug":462,"hasResults":11,"nctId":463,"briefTitle":464,"officialTitle":465,"acronym":466,"eligibilityCriteria":467,"healthyVolunteers":266,"sex":16,"minAge":17,"maxAge":468,"enrollmentInfo":469,"targetDuration":4,"studyType":93,"phases":4,"briefSummary":470,"conditions":471,"keywords":472,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":478,"lastUpdatePostDateStruct":479,"startDateStruct":481,"completionDateStruct":483,"leadSponsor":485,"locationsCount":83},"100513376","echocardiography-based-motion-integration-and-management-for-substrate-characterization-and-star-therapy-in-ventricular-tachycardias-100513376","NCT05964660","Echocardiography-based Motion Integration and Management for Substrate Characterization and STAR Therapy in Ventricular Tachycardias","New 3D-echocardiography-based Motion Integration and mAnagement for subsTrate characteRisation and Stereotactic Arrhythmia radIoablation tX in Ventricular Tachycardias- the MATRIX-VT Study","MATRIX-VT","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Indication for catheter ablation of ventricular arrhythmias (ventricular fibrillation, ventricular tachycardia, premature ventricular contractions)\n* Indication for preprocedural contrast-enhanced cardiac computed tomography for cardiac structure characterization\n\nExclusion Criteria:\n\n* Platelet count \\\u003C 100,000 cells\u002Fmm3\n* BMI \\> 45 kg\u002Fm2 or \\\u003C 18 kg\u002Fm2","100 Years",{"count":92,"type":20},"Prospective, observational, single center, pilot study to analyze the feasibility of motion and structural data integration in patients with ventricular arrhythmia by means of artificial intelligence for improved arrhythmogenic substrate characterization and motion management during stereotactic arrhythmia radioablation.",[26],[473,474,475,273,476,477],"Ventricular arrhythmia","Ventricular tachycardia","Stereotactic arrhythmia radioablation","Motion management","Motion integration","2024-08-28",{"date":480,"type":36},"2024-08-29",{"date":482,"type":36},"2023-08-14",{"date":484,"type":20},"2025-03",{"name":486,"class":82},"University of Luebeck",{"id":488,"slug":489,"hasResults":11,"nctId":490,"briefTitle":491,"officialTitle":492,"acronym":4,"eligibilityCriteria":493,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":494,"targetDuration":4,"studyType":21,"phases":495,"briefSummary":496,"conditions":497,"keywords":498,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":500,"lastUpdatePostDateStruct":501,"startDateStruct":503,"completionDateStruct":505,"leadSponsor":507,"locationsCount":83},"100547701","sbrt-for-ventricular-arrhythmia-100547701","NCT06411392","SBRT for Ventricular Arrhythmia","Stereotactic Antiarrhythmic Radiotherapy for Ventricular Arrhythmia in Austria (Austrian STAR)","Inclusion Criteria:\n\n* Recurrent VTs\u002FVES with significant burden despite guideline-directed therapy\n* Existing protective ICD (Implantable cardioverter-defibrillator) implantation except in the presence of contraindications\n* AND lack of response or intolerance to antiarrhythmic medication\n* AND status post ≥1 catheter ablation due to monomorphic VT(s) and VT early recurrence (\\\u003C12 months after the last catheter ablation) OR contraindication for endocardial ablation (mechanical valve prosthesis, LV (left ventricular) thrombus, or lack of vascular access in suspicion of endocardial substrate)\n* MINIMAL VT BURDEN: The patient must have had at least 3 VT episodes (sustained VT, ICD-ATP, or ICD shock) in the last 3 months prior to study enrollment.\n* Presence of suitability for radiation therapy with respect to SBRT\n* Age ≥ 18 years\n* Existing informed consent\n\nExclusion Criteria:\n\n* Acute myocardial infarction or percutaneous coronary intervention or heart surgery (\\\u003C3 months before study enrollment)\n* Status post intra-thoracic pre-radiation\n* Immediate proximity to radiosensitive structures (e.g., esophagus) making therapy unsafe to administer\n* Advanced symptomatic heart failure (NYHA Class IV)\n* Polymorphic VT or ventricular fibrillation (confirmed in 12-lead ECG and\u002For ICD interrogation)\n* Extensive myocardial scar substrate that would result in too large of a radiation volume\n* Life expectancy \\\u003C 6 months considering all comorbidities and in the Seattle Heart Failure Model\n* Presence of a Left Ventricular Assist Device (LVAD)\n* Use of cytotoxic medications\n* Pregnancy or lactation - negative pregnancy test within 14 days before study entry required for women of childbearing potential",{"count":140,"type":20},[23],"The aim of this study is to demonstrate the safety and efficacy of STAR (Stereotactic Antiarrhythmic Radiotherapy) in patients with VT (ventricular tachycardia) who are unresponsive to standard treatments. Additionally, the planned study aims to provide further insights into the effects of STAR on VT burden, ICD interventions, and insights regarding late toxicities, particularly those related to the heart, which are currently not well understood.",[26],[499],"stereotactic radiotherapy","2024-05-08",{"date":502,"type":36},"2024-05-13",{"date":504,"type":36},"2024-03-01",{"date":506,"type":20},"2027-02",{"name":508,"class":82},"Medical University of Graz",{"id":510,"slug":511,"hasResults":11,"nctId":512,"briefTitle":513,"officialTitle":514,"acronym":515,"eligibilityCriteria":516,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":171,"enrollmentInfo":517,"targetDuration":4,"studyType":93,"phases":4,"briefSummary":518,"conditions":519,"keywords":520,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":523,"lastUpdatePostDateStruct":524,"startDateStruct":526,"completionDateStruct":528,"leadSponsor":530,"locationsCount":83},"100513431","risk-stratification-value-of-biomarkers-in-patients-with-ventricular-arrhythmias-100513431","NCT05965375","Risk Stratification Value of Biomarkers in Patients With Ventricular Arrhythmias","Risk Stratification Value of Biomarkers in Patients With Ventricular Arrhythmias (FUTURE): an Investigator-initiated, National, Multicenter, Retrospective-prospective, Cohort Study","FUTURE","Inclusion Criteria:\n\n* Patients with ventricular premature beats, ventricular tachycardia, or ventricular fibrillation detected by regular surface twelve-lead electrocardiogram or Holter.\n\nExclusion Criteria:\n\n* Age \\\u003C18 or \\>80 years old;\n* Patients with autoimmune diseases or immune deficiencies, or those who have used immunosuppressive or immune modulating agents in the past 3 months;\n* Platelet count \\\u003C100×10\\^9\u002FL or functional platelet defects;\n* Congenital or acquired coagulation or bleeding disorders;\n* Patients with a history of organ transplantation or are preparing to receive organ transplantation;\n* Unwilling to sign an informed consent or cooperate with the examination.",{"count":268,"type":20},"The investigation of biomarkers for immune status and metabolic state, as well as host microbiota composition, in patients with ventricular arrhythmias before and after radiofrequency ablation, can provide new insights for specific and personalized treatment. This can help establish early prediction and prognosis models and provide a basis for clinically effective diagnosis and treatment.",[26],[521,522],"Ventricular Arrhythmia","Prognosis","2024-04-02",{"date":525,"type":36},"2024-04-04",{"date":527,"type":20},"2024-12-31",{"date":529,"type":20},"2027-05-31",{"name":531,"class":82},"First Affiliated Hospital Xi'an Jiaotong University",{"id":533,"slug":534,"hasResults":11,"nctId":535,"briefTitle":536,"officialTitle":537,"acronym":538,"eligibilityCriteria":539,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":540,"targetDuration":4,"studyType":93,"phases":4,"briefSummary":542,"conditions":543,"keywords":564,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":576,"lastUpdatePostDateStruct":577,"startDateStruct":579,"completionDateStruct":581,"leadSponsor":583,"locationsCount":585},"100541040","contemporary-cardiac-stimulation-in-clinical-practice-left-biventricular-right-and-conduction-system-pacing-100541040","NCT06324682","ConTempoRary Cardiac Stimulation in Clinical practicE: lEft, BivEntriculAr, Right, and conDuction System Pacing","Evaluation of conTempoRary Cardiac Stimulation in Clinical practicE: lEft, BivEntriculAr, Right, and conDuction System Pacing","TREEBEARD","Inclusion Criteria:\n\n* Indication for cardiac stimulation\n* Having performed the implantation of a device for cardiac stimulation\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years;\n* Pregnancy status;",{"count":541,"type":20},8400,"The goal of this observational study is to evaluate the clinical characteristics of patients undergoing permanent cardiac pacing and to compare procedural efficacy and safety of different implantation approaches in the clinical practice of the participating centres. The contribution of non-fluoroscopic anatomical and electrophysiological reconstruction systems to device implantation procedures will also be evaluated.\n\nParticipants \\[patients over 18 years old with an indication to receive a definitive pacemaker\u002Fintracardiac defibrillator implant\\] will receive a permanent cardiac pacing implant as requested according to European Society of Cardiology (ESC) guidelines; the investigators will evaluate procedural efficacy and safety of different implantation approaches.",[201,544,545,155,546,28,547,27,26,548,549,550,551,552,553,554,555,556,557,558,559,560,561,562,563],"Atrioventricular Block","Reduced Systolic Function","Bradyarrhythmia","Ventricular Dysfunction","Atrioventricular Nodal Disease","Atrioventricular Conduction Defects","Atrioventricular Block Complete","Atrioventricular Block Incomplete","Atrioventricular Junctional Rhythm","Bundle-Branch Block","Left Bundle-Branch Block","Heart Failure, Systolic","Block;Atrioventricular","Block; Arrhythmic","Block; Mobitz","Block, Heart","Block, Fascicular","Block Branch Bundle Left","Heart Failure，Congestive","Heart Arrhythmia",[565,566,544,546,547,567,568,569,570,571,572,573,574,550,575,26,27,28],"Pace maker (PM)","Implantable cardioverter defibrillator (ICD)","Cardiac Resynchronization therapy","Conduction System Pacing","His Pacing","Left bundle branch area pacing (LBBAP)","CRT","CSP","Primary prevention","Secondary prevention","Heart failure","2024-03-19",{"date":578,"type":36},"2024-03-22",{"date":580,"type":36},"2023-01-01",{"date":582,"type":20},"2034-12-31",{"name":584,"class":82},"University Hospital of Ferrara",31,{"id":587,"slug":588,"hasResults":11,"nctId":589,"briefTitle":590,"officialTitle":591,"acronym":4,"eligibilityCriteria":592,"healthyVolunteers":11,"sex":16,"minAge":593,"maxAge":295,"enrollmentInfo":594,"targetDuration":4,"studyType":93,"phases":4,"briefSummary":596,"conditions":597,"keywords":598,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":604,"lastUpdatePostDateStruct":605,"startDateStruct":607,"completionDateStruct":609,"leadSponsor":611,"locationsCount":83},"100353347","china-inherited-ventricular-arrhythmias-registry-100353347","NCT03880708","China Inherited Ventricular Arrhythmias Registry","China Inherited Ventricular Arrhythmias Registry, a Multicenter, Observational and Prospective Study","Inclusion Criteria:\n\n* diagnosed as Brugada syndrome(Brs)、Long QT syndrome(LQTS)、Short QT syndrome(SQTS)、Early repolarization syndrome(ERS) or Catecholaminergic polymorphic ventricular tachycardia(CPVT).\n\nExclusion Criteria:\n\n* patients were enrolled by other clinical trials.","1 Hour",{"count":595,"type":20},500,"This is an observational, prospective, multi-center registry, aiming at building a risk stratification for malignant inherited ventricular arrhythmias, including Brugada syndrome(Brs)、Long QT syndrome(LQTS)、Short QT syndrome(SQTS)、Early repolarization syndrome(ERS) and Catecholaminergic polymorphic ventricular tachycardia(CPVT). 500 participants will be recruited from 10 centers in China, with clinical data to be abstracted from medical records, and blood samples to be collected for finding related genes and promising risk indicators. The follow-up should be made every 6 months.",[26],[599,600,601,602,603],"brugada syndrome","long QT syndrome","short QT syndrome","early repolarization syndrome","catecholaminergic polymorphic ventricular tachycardia","2019-03-22",{"date":606,"type":36},"2019-03-26",{"date":608,"type":36},"2017-10-24",{"date":610,"type":20},"2027-10-24",{"name":612,"class":613},"China National Center for Cardiovascular Diseases","OTHER_GOV",{"id":615,"slug":616,"hasResults":11,"nctId":617,"briefTitle":618,"officialTitle":618,"acronym":619,"eligibilityCriteria":620,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":621,"targetDuration":623,"studyType":93,"phases":4,"briefSummary":624,"conditions":625,"keywords":630,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":635,"lastUpdatePostDateStruct":636,"startDateStruct":638,"completionDateStruct":640,"leadSponsor":642,"locationsCount":83},"100350035","french-national-registry-of-patients-with-tetralogy-of-fallot-and-implantable-cardioverter-defibrillator-100350035","NCT03837574","French National Registry of Patients With Tetralogy of Fallot and Implantable Cardioverter Defibrillator","DAI-T4F","Inclusion Criteria:\n\n* tetralogy of Fallot\n* implantable cardioverter defibrillator\n\nExclusion Criteria:\n\n* age \\\u003C 18 years",{"count":622,"type":20},150,"20 Years","National french registry of patients with tetralogy of Fallot and implantable cardioverter defibrillator.",[626,627,628,629,26],"Tetralogy of Fallot","Implantable Defibrillator User","Congenital Heart Disease","Sudden Cardiac Death",[631,632,633,634,325],"tretalogy of fallot","implantable cardioverter defibrillator","congenital heart disease","sudden cardiac death","2019-02-09",{"date":637,"type":36},"2019-02-12",{"date":639,"type":36},"2010-12-01",{"date":641,"type":20},"2030-12-31",{"name":643,"class":82},"Paris Sudden Death Expertise Center",{"id":645,"slug":646,"hasResults":11,"nctId":647,"briefTitle":648,"officialTitle":649,"acronym":4,"eligibilityCriteria":650,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":651,"targetDuration":653,"studyType":93,"phases":4,"briefSummary":654,"conditions":655,"keywords":656,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":663,"lastUpdatePostDateStruct":664,"startDateStruct":666,"completionDateStruct":667,"leadSponsor":668,"locationsCount":83},"100348765","china-structural-ventricular-arrhythmias-registry-100348765","NCT03821051","China Structural Ventricular Arrhythmias Registry","China Structural Ventricular Arrhythmias Registry, a Multicenter，Observational and Prospective Study.","Inclusion Criteria:\n\n* diagnosed as ventricular arrhythmia resulted by structural heart diseases, including ischemic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, dilated cardiomyopathy, hypertrophic cardiomyopathy, etc.\n\nExclusion Criteria:\n\n* none",{"count":652,"type":20},2000,"5 Years","This is an observational, prospective, multi-center registry ,aiming at building a risk stratification for malignant structural ventricular arrhythmias. 2000 participants will be recruited from 10 centers in China,with clinical data to be abstracted from medical records ,and blood samples to be collected for finding promising risk indicators.The follow-up should be made every 6 mouths.",[26],[657,658,659,660,661,662],"structural ventricular arrythmia","ischemic cardiomyopathy","arrhythmogenic right ventricular cardiomyopathy","dilated cardiomyopathy","hypertrophic cardiomyopathy","risk stratification","2019-01-27",{"date":665,"type":36},"2019-01-29",{"date":608,"type":36},{"date":610,"type":20},{"name":612,"class":613}]